Genmab — November 2020
-
https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/88181_genmab_rykker.JPG Tror vi skal op og ligge og swinge mellem 2350 til 2650 kommende måneder. Har indikeret en mindre stejl kurve. Har selvfølgelig ikke ikke noget imod Genmab forbliver i den stejle kurve
-
Genmab/CEO: Darzalex suppleres af flere nye trækheste i 2021
https://www.proinvestor.com/investornyt/669340/genmab-ceo-darzalex-suppleres-af-flere-nye-traekheste-i-2021 -
Janssen Seeks Expanded Use of DARZALEX
▼ (daratumumab) Subcutaneous Formulation for the Treatment of Patients with Light Chain (AL) Amyloidosis https://www.businesswire.com/news/home/20201105005525/en/Janssen-Seeks-Expanded-Use-of-DARZALEX▼-daratumumab-Subcutaneous-Formulation-for-the-Treatment-of-Patients-with-Light-Chain-AL-Amyloidosis -
and Genmab also announcing the EMA s
ubmission https://ir.genmab.com/news-releases/news-release-details/genmab-announces-janssen-has-submitted-type-ii-variation -
Genmab-partner søger om tillægsgodkendelse for Darzalex i Europa - NY
https://www.proinvestor.com/investornyt/669343/genmab-partner-soger-om-tillaegsgodkendelse-for-darzalex-i-europa-ny -
Jeg minder lige om denne analyse:
https://www.proinvestor.com/boards/86703/Teknisk-analyse-af-Genmab -
-
About Non-Small Cell Lung Cancer (NSCLC)
In the U.S., lung cancer is the second most common cancer in both men and women, after skin cancer; NSCLC makes up 80-85 percent of all lung cancers.[8],[9] The main subtypes of NSCLC are adenoca rcinoma, squamous cell carcinoma, and large cell carcinoma.10 The most common driver mutation for NSCLC is the EGFR genetic alteration, which is a receptor tyrosine kinase that helps cells grow and divide.[10] -
EGFR mutations are present in 10 to 15 percent of patients with NSCLC and occur in 40 to 50 percent of Asian patients who have NSCLC adenocarcinoma.[11],[12],[13] EGFR exon 20 insertion mutations identify a distinct subset of lung adenocarcinomas, accounting for at least nine percent of all EGFR mutations.[14] The five-year survival rate for patients with metastatic NSCLC is currently six percent.[15]
Judith did tell that they will persude all b-cell indications.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind